CARDIOFOCUS, INC.

CardioFocus, Inc. is a medical device manufacturer specializing in innovative ablation technologies for treating cardiac arrhythmias, particularly atrial fibrillation (AFib). The company develops and manufactures advanced catheter-based pulsed field ablation (PFA) systems that emphasize precision and minimally invasive therapy. The flagship HeartLight Endoscopic Ablation System, FDA-approved in 2016, features an ultra-compliant balloon catheter with direct visualization for pulmonary vein isolation. The company's current PFA portfolio includes the CENTAURI System (the platform that defined focal PFA), OptiShot balloon catheter (investigational, designed for circumferential pulmonary vein isolation with endoscopic confirmation), QuickShot Nav catheter (investigational, a versatile large-area focal PFA device with integrated mapping and ablation), and the CardioWave System (investigational, a modular next-generation PFA generator supporting multiple catheter types). CardioFocus has treated over 10,000 patients worldwide and maintains global distribution partnerships in Japan, Europe, and China, positioning it as a key player in electrophysiology and cardiac ablation markets.